Your browser is no longer supported. Please, upgrade your browser.
Settings
BTX BioTime, Inc. daily Stock Chart
BTX [NYSE]
BioTime, Inc.
Index- P/E6.15 EPS (ttm)0.43 Insider Own5.30% Shs Outstand128.88M Perf Week-2.22%
Market Cap340.24M Forward P/E- EPS next Y-0.31 Insider Trans66.32% Shs Float118.41M Perf Month12.34%
Income46.90M PEG- EPS next Q-0.07 Inst Own39.10% Short Float5.68% Perf Quarter-1.86%
Sales3.50M P/S97.21 EPS this Y156.70% Inst Trans0.29% Short Ratio16.53 Perf Half Y-10.20%
Book/sh1.72 P/B1.53 EPS next Y-186.10% ROA24.60% Target Price6.17 Perf Year-17.76%
Cash/sh0.14 P/C18.69 EPS next 5Y- ROE27.60% 52W Range2.10 - 3.62 Perf YTD22.79%
Dividend- P/FCF- EPS past 5Y24.20% ROI-8.10% 52W High-27.07% Beta1.71
Dividend %- Quick Ratio- Sales past 5Y6.00% Gross Margin97.30% 52W Low25.71% ATR0.12
Employees100 Current Ratio3.90 Sales Q/Q13.30% Oper. Margin- RSI (14)59.51 Volatility3.44% 5.62%
OptionableYes Debt/Eq0.01 EPS Q/Q-58.70% Profit Margin- Rel Volume0.47 Prev Close2.66
ShortableYes LT Debt/Eq0.01 EarningsFeb 08 AMC Payout0.00% Avg Volume406.89K Price2.64
Recom1.70 SMA206.97% SMA507.14% SMA200-6.52% Volume191,419 Change-0.75%
Mar-31-17Initiated Raymond James Outperform $6
Sep-23-16Initiated Ladenburg Thalmann Buy
Feb-19-16Initiated Chardan Capital Markets Buy $5
Dec-22-15Initiated Oppenheimer Outperform $10
Dec-19-11Upgrade WBB Securities Buy → Strong Buy $8
Nov-16-11Upgrade WBB Securities Speculative Buy → Buy $6 → $8
Aug-11-11Initiated WBB Securities Speculative Buy $6
Jan-06-11Initiated BioLogic Equity Research Sell $2
Jan-18-18 07:00AM  AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on Stem Cell Innovations That Will Change the World Business Wire
Jan-17-18 07:00AM  BioTime Announces Issuance of 41 New Patents to Expand and Bolster Its Patent Estate Business Wire
Jan-05-18 04:30PM  AgeX Therapeutics to Present at Biotech Showcase Annual Conference Business Wire
Jan-02-18 07:00AM  AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer Business Wire +6.51%
Dec-29-17 11:38AM  ETFs with exposure to BioTime, Inc. : December 29, 2017 Capital Cube
Dec-20-17 07:49AM  Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys Zacks
07:00AM  BioTime to Participate in The LifeSci Advisors Corporate Access Event in San Francisco, January 8 10, 2018 Business Wire
Dec-19-17 06:23AM  Try Rising P/E Investing With 5 Top-Ranked Stocks Zacks
Dec-18-17 02:59PM  ETFs with exposure to BioTime, Inc. : December 18, 2017 Capital Cube
Dec-07-17 01:06PM  ETFs with exposure to BioTime, Inc. : December 7, 2017 Capital Cube
Dec-05-17 09:35AM  Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys Zacks
08:53AM  BioTime, Inc. :BTX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017 Capital Cube
Dec-04-17 08:00AM  Additional Renevia Data From the Successful Pivotal Trial Was Presented at the IFATS Conference Business Wire
07:00AM  AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis Americas Annual Conference on Tissue Engineering & Regenerative Medicine, December 6 in Charlotte, NC Business Wire
Dec-01-17 09:33AM  Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime Zacks
Nov-30-17 08:20AM  5 Affordable Breakout Stocks Offering Excellent Returns Zacks
07:00AM  Data from BioTimes Renevia® Program to Be Presented at IFATS Conference Business Wire
Nov-29-17 02:03AM  BioTime, Inc. is trading above its 50 day moving average : BTX-US : November 29, 2017 Capital Cube
Nov-28-17 01:37PM  BioTime, Inc. Value Analysis (NYSE AMERICAN:BTX) : November 28, 2017 Capital Cube
Nov-27-17 07:30AM  BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : November 27, 2017 Capital Cube
Nov-15-17 11:13AM  BioTime, Inc.: Trading close to its 50 day moving average. Good buy? Capital Cube
08:00AM  BioTime Presents Updated OpRegen® Phase I/IIa Trial Data at AAO Business Wire
Nov-14-17 12:41AM  Edited Transcript of BTX earnings conference call or presentation 9-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-13-17 07:00AM  BioTime to Participate in Upcoming Conferences Business Wire -5.08%
Nov-10-17 11:58AM  ETFs with exposure to BioTime, Inc. : November 10, 2017 Capital Cube +13.78%
Nov-09-17 04:59PM  BioTime beats 3Q profit forecasts Associated Press
04:05PM  BioTime Reports Third Quarter Results and Recent Corporate Accomplishments Business Wire
02:40PM  Edited Transcript of BTX earnings conference call or presentation 2-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
12:25PM  Is It Time To Buy BioTime Inc (BTX)? Simply Wall St.
Nov-08-17 07:00AM  AgeX Therapeutics VP of New Technology Discovery Aubrey de Grey to Serve on Aging & Longevity Panel at FT Global Pharmaceutical and Biotechnology Conference, November 9-10 in London Business Wire
Nov-02-17 12:00AM  BioTime to Participate in the Jefferies 2017 London Healthcare Conference Business Wire
Oct-26-17 10:22AM  ETFs with exposure to BioTime, Inc. : October 26, 2017 Capital Cube
07:00AM  AgeX Therapeutics CEO Michael D. West to Give Special Interview for The Economists Conference The Business of Longevity: Health Innovation for an Ageing World October 27 in Hong Kong Business Wire
Oct-24-17 07:00AM  BioTime to Announce Third Quarter 2017 Results on November 9, 2017 Business Wire
Oct-18-17 03:03AM  BioTime, Inc. is trading below its 50 day moving average : BTX-US : October 18, 2017 Capital Cube
Oct-17-17 04:05PM  BioTime, Inc. Announces Closing of Public Offering and Underwriters Full Exercise of Over-Allotment Option Business Wire
Oct-13-17 09:15AM  BioTime, Inc. Announces Pricing of $25.0 Million Public Offering of Common Stock Business Wire
07:10AM  Corporate News Blog - BioTime to Sublicense Hystem(R) to Processa Pharma for Developing Drug Delivery Platforms ACCESSWIRE
Oct-12-17 04:05PM  BioTime, Inc. Announces Proposed Public Offering of Common Stock Business Wire
Oct-11-17 08:00AM  BioTime Announces First Patient in U.S. Clinical Trial Treated for Facial Volume Deficit Business Wire
07:00AM  BioTime and Processa Announce Their Intention to Enter into a HyStem® Sublicense for Drug Delivery Business Wire
Oct-04-17 10:37AM  ETFs with exposure to BioTime, Inc. : October 4, 2017 Capital Cube
Oct-03-17 07:00AM  BioTime to Present at the Cell and Gene Meeting on the Mesa Business Wire
Sep-26-17 07:00AM  BioTime Announces Positive Secondary and Additional Positive Long-Term Data from the Renevia® Pivotal Trial Business Wire
Sep-25-17 07:00AM  BioTime Board of Directors Approves Distribution of AgeX Therapeutics Shares to BioTime Shareholders Business Wire
Sep-22-17 11:05AM  ETFs with exposure to BioTime, Inc. : September 22, 2017 Capital Cube
09:00AM  BioTime - A Multi-Faceted Regenerative Medicine Company ACCESSWIRE
Sep-21-17 12:10PM  BioTime, Inc. :BTX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017 Capital Cube
10:16AM  BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : September 21, 2017 Capital Cube
07:00AM  BioTime Co-CEO Adi Mohanty to Participate in Panel Discussion at the Cell & Gene Therapy CEO Forum Business Wire
07:00AM  AgeX Therapeutics CEO Michael D. West to Participate in Fireside Chat with J. Craig Venter at the Cell & Gene Therapy CEO Forum Business Wire
03:09AM  BioTime, Inc. is trading above its 50 day moving average : BTX-US : September 21, 2017 Capital Cube
Sep-20-17 07:00AM  BioTime to Present at the Ladenburg Thalmann 2017 Healthcare Conference Business Wire
07:00AM  BioTime to Present at the Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-18-17 07:00AM  BioTime Awarded Grant from the NIH Business Wire
Sep-14-17 05:43PM  Two Key BioTime Patents Providing Protection to OpRegen® Remain Upheld Business Wire
Sep-11-17 09:55PM  ETFs with exposure to BioTime, Inc. : September 12, 2017 Capital Cube
Sep-08-17 08:58PM  BioTime, Inc. :BTX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 9, 2017 Capital Cube
07:00AM  BioTime to Present at the Rodman & Renshaw Annual Global Investment Conference Business Wire
Sep-05-17 07:00AM  BioTime to Present at the LD Micro San Francisco Summit Business Wire
Sep-01-17 09:48AM  BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : September 1, 2017 Capital Cube
Aug-28-17 07:00AM  BioTime to Present Data at the Military Health System Research Symposium Business Wire
Aug-17-17 07:00AM  AgeX Therapeutics Closes $10 Million Capital Raise Business Wire
Aug-14-17 07:00AM  BioTime Announces $2 Million Grant for Further Development of OpRegen® for Dry-AMD Business Wire
Aug-09-17 07:00AM  AgeX Therapeutics CEO Michael D. West, Ph.D. to Deliver Keynote Address on Biotechnology and Aging at RAAD Festival Business Wire
Aug-04-17 02:34AM  BioTime reports 2Q loss Associated Press
Aug-02-17 04:10PM  BioTime Reports Second Quarter Results and Recent Corporate Accomplishments Business Wire
10:00AM  Investor Network: BIOTIME INC to Host Earnings Call ACCESSWIRE
08:30AM  AgeX Therapeutics Obtains $10 Million in Capital and Commences Operations Business Wire
Jul-31-17 05:42PM  BioTime, Inc. Value Analysis (NYSE MKT:BTX) : July 31, 2017 Capital Cube
Jul-25-17 04:30PM  BioTime Receives DSMB Approval to Start Third Patient Cohort in Clinical Trial for Dry-AMD; Commences Patient Enrollment in the US Business Wire
Jul-20-17 07:00AM  BioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017 Business Wire
Jul-19-17 07:00AM  Data From BioTimes Phase I/IIa OpRegen® Trial to be Presented at the 2017 American Academy of Ophthalmology (AAO) Annual Meeting Business Wire
Jul-18-17 07:00AM  BioTime to Host Key Opinion Leader Event on the Topic of Dry AMD in New York City Business Wire
Jul-14-17 08:29AM  BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : July 14, 2017 Capital Cube
Jul-13-17 07:00AM  BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery Business Wire
Jun-26-17 09:46AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating BioTime, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
08:37AM  BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : June 26, 2017 Capital Cube
Jun-19-17 07:00AM  Biotime Expands & Advances Ophthalmology Portfolio Business Wire
Jun-14-17 08:19AM  BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : June 14, 2017 Capital Cube -8.58%
07:00AM  BioTimes Renevia® Achieves Primary Endpoint in European Pivotal Trial Business Wire
06:00AM  BioTime's Renevia succeeds in pivotal European facial wasting trial Reuters
Jun-08-17 04:10PM  BioTime to Announce Top Line Data From the Companys Renevia European Pivotal trial Business Wire
Jun-05-17 02:04PM  ETFs with exposure to BioTime, Inc. : June 5, 2017 Capital Cube
Jun-02-17 09:56AM  BioTime, Inc. :BTX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-29-17 08:20AM  BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : May 29, 2017 Capital Cube
May-25-17 03:00AM  BioTime, Inc. breached its 200 day moving average in a Bullish Manner : BTX-US : May 25, 2017 Capital Cube
May-23-17 04:30PM  BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics Strategic Investment Conference on May 24 Business Wire
07:00AM  BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED) Business Wire
May-11-17 08:18AM  Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1 Zacks
07:00AM  BioTime Presents Retinal Restoration Data at ARVO Business Wire
May-10-17 04:18PM  BioTime posts 1Q profit Associated Press
04:01PM  BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments Business Wire
03:48PM  Valeant (VRX) Q1 Earnings & Revenues Miss, View Raised Zacks
01:52PM  Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View Zacks
09:58AM  Infinity (INFI) Reports Narrower-than-Expected Loss in Q1 Zacks
May-09-17 07:00AM  BioTime Announces New Positive Data from OpRegen® Trial in Dry-AMD Business Wire
May-08-17 02:40PM  BioTime, Inc. : Undervalued relative to peers, but dont ignore the other factors Capital Cube
07:00AM  BioTime Co-CEO Dr. Michael D. West to Present at World Advanced Therapies & Regenerative Medicine Congress on May 17 and 19 Business Wire
May-05-17 03:05AM  BioTime, Inc. is trading below its 50 day moving average : BTX-US : May 5, 2017 Capital Cube
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is based in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WEST MICHAEL DCo-Chief Executive OfficerJan 10Option Exercise0.001,5620885,401Jan 12 08:30 PM
MOHANTY ADITYA P.Co-Chief Executive OfficerJan 10Option Exercise0.004,687097,309Jan 12 09:17 PM
BROADWOOD PARTNERS, L.P.DirectorOct 13Buy2.602,692,3076,999,99829,971,561Oct 17 05:58 PM
MOHANTY ADITYA P.Co-Chief Executive OfficerOct 10Option Exercise0.004,688094,384Oct 12 09:35 PM
WEST MICHAEL DCo-Chief Executive OfficerOct 10Option Exercise0.001,5630884,427Oct 12 07:35 PM
SKIBSTED RUSSELLChief Financial OfficerAug 23Buy2.642,0005,2852,000Aug 25 04:33 PM
BROADWOOD PARTNERS, L.P.DirectorAug 22Buy2.6010,00025,95527,279,254Aug 24 06:58 PM
WEST MICHAEL DCo-Chief Executive OfficerAug 22Buy2.602,0005,198882,864Aug 23 07:23 PM
ANDREWS DEBORAH JDirectorAug 21Buy2.502,3965,9908,396Aug 23 06:31 PM
Patton Stephana EileneGeneral CounselAug 21Buy2.587,50019,3767,500Aug 22 08:43 PM
MOHANTY ADITYA P.Co-Chief Executive OfficerAug 21Buy2.507,50018,75089,696Aug 22 08:22 PM
BROADWOOD PARTNERS, L.P.DirectorJul 31Buy2.80150,000420,00027,269,254Aug 02 06:37 PM
KINGSLEY ALFRED DSee RemarksJul 31Sale2.80150,000420,0005,781,555Aug 02 06:27 PM
MOHANTY ADITYA P.Co-Chief Executive OfficerJul 10Option Exercise0.004,687083,958Jul 12 07:26 PM
WEST MICHAEL DCo-Chief Executive OfficerJul 10Option Exercise0.001,5620881,451Jul 12 07:21 PM
ANDREWS DEBORAH JDirectorJun 16Buy2.952,0005,9006,000Jun 21 08:19 PM
ANDREWS DEBORAH JDirectorMay 16Buy3.212,0006,4104,000May 17 08:52 PM
MOHANTY ADITYA P.Co-Chief Executive OfficerApr 10Option Exercise0.0018,750086,317May 01 09:18 PM
WEST MICHAEL DCo-Chief Executive OfficerApr 10Option Exercise0.006,2500882,237May 01 08:58 PM
BROADWOOD PARTNERS, L.P.DirectorFeb 15Buy2.702,222,2225,999,99927,119,254Feb 17 05:02 PM